Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia

[1]  G. Ehninger,et al.  Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system , 2014, Leukemia.

[2]  I. Bernstein,et al.  SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. , 2013, Blood.

[3]  O. Landt,et al.  The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. , 2013, Blood.

[4]  B. Löwenberg,et al.  Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. , 2013, Blood.

[5]  N. Schmitz,et al.  Impact of allogeneic haematopoietic stem cell transplantation in patients with abnl(17p) acute myeloid leukaemia , 2013, British journal of haematology.

[6]  A. Mackensen,et al.  T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct , 2013, Leukemia.

[7]  G. Ehninger,et al.  Redirection of T cells with a first fully humanized bispecific CD33–CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells , 2013, Leukemia.

[8]  M. Boyiadzis,et al.  CD123 Immunohistochemical Expression in Acute Myeloid Leukemia is Associated With Underlying FLT3-ITD and NPM1 Mutations , 2012, Applied immunohistochemistry & molecular morphology : AIMM.

[9]  R. Hills,et al.  The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison , 2013, Leukemia.

[10]  Joshua F. McMichael,et al.  The Origin and Evolution of Mutations in Acute Myeloid Leukemia , 2012, Cell.

[11]  I. Bernstein,et al.  Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. , 2012, Blood.

[12]  S. Jang,et al.  Flow cytometric quantification and immunophenotyping of leukemic stem cells in acute myeloid leukemia , 2012, Annals of Hematology.

[13]  H. Dombret,et al.  Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study , 2012, The Lancet.

[14]  G. Fey,et al.  Dual-Targeting for the Elimination of Cancer Cells with Increased Selectivity , 2012 .

[15]  Joshua F. McMichael,et al.  Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.

[16]  I. Bernstein,et al.  Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. , 2008, Blood.

[17]  R. Foà,et al.  High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation , 2011, Haematologica.

[18]  Angelo J. Canty,et al.  Stem cell gene expression programs influence clinical outcome in human leukemia , 2011, Nature Medicine.

[19]  G. Ehninger,et al.  Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  N. Schmitz,et al.  Cytarabine dose of 36 g/m² compared with 12 g/m² within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Hermann Einsele,et al.  Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  F. Lo‐Coco,et al.  Immunophenotypic features of acute myeloid leukaemia patients exhibiting high FLT3 expression not associated with mutations , 2011, British journal of haematology.

[23]  P. Vyas,et al.  Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. , 2011, Cancer cell.

[24]  W. Gorczyca,et al.  Immunophenotypic pattern of myeloid populations by flow cytometry analysis. , 2011, Methods in cell biology.

[25]  D. Saul,et al.  A recombinant trispecific single‐chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting , 2010, British journal of haematology.

[26]  J. Gribben,et al.  Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. , 2010, Blood.

[27]  A. Mackensen,et al.  Novel conjugates of single‐chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells , 2010, British journal of haematology.

[28]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[29]  W. Helfrich,et al.  Targeted elimination of leukemia stem cells; a new therapeutic approach in hemato-oncology. , 2010, Current drug targets.

[30]  G. Ehninger,et al.  HLA‐DRneg patients without acute promyelocytic leukemia show distinct immunophenotypic, genetic, molecular, and cytomorphologic characteristics compared to acute promyelocytic leukemia , 2009, Cytometry. Part B, Clinical cytometry.

[31]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[32]  J. Dick,et al.  Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. , 2009, Cell stem cell.

[33]  R. Foà,et al.  Interleukin (IL)‐3/granulocyte macrophage‐colony stimulating factor/IL‐5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS‐related tyrosine kinase 3 receptor , 2009, British journal of haematology.

[34]  T. Robak,et al.  Current and emerging therapies for acute myeloid leukemia. , 2009, Clinical therapeutics.

[35]  M. Patnaik,et al.  Anthracycline dose intensification in acute myeloid leukemia. , 2009, The New England journal of medicine.

[36]  P. Chevallier,et al.  Persistence of CD33 expression at relapse in CD33+ acute myeloid leukaemia patients after receiving Gemtuzumab in the course of the disease , 2008, British journal of haematology.

[37]  J. Gribben,et al.  Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. , 2008, Blood.

[38]  J. Hoyer,et al.  CD33 detection by immunohistochemistry in paraffin-embedded tissues: a new antibody shows excellent specificity and sensitivity for cells of myelomonocytic lineage. , 2008, American journal of clinical pathology.

[39]  Robert E. Lewis,et al.  Contrasting antigenic maturation patterns in M0-M2 versus M3 acute myeloid leukemias. , 2007, Experimental and molecular pathology.

[40]  I. Bernstein,et al.  CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. , 2007, Blood.

[41]  D. Printz,et al.  Expression of the target receptor CD33 in CD34+/CD38−/CD123+ AML stem cells , 2007, European journal of clinical investigation.

[42]  R. Bouabdallah,et al.  High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group , 2007, Leukemia.

[43]  V. Diehl,et al.  Immunophenotyping of surface antigens in acute myeloid leukemia by flow cytometry after red blood cell lysis. , 2007, Leukemia research.

[44]  Gerhard Ehninger,et al.  Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). , 2006, Blood.

[45]  P. Valent,et al.  Detection of molecular targets on the surface of CD34+/CD38− stem cells in various myeloid malignancies , 2006, Leukemia & lymphoma.

[46]  Gerhard Ehninger,et al.  Prevalence and prognostic impact of NPM 1 mutations in 1485 adult patients with acute myeloid leukemia ( AML ) , 2006 .

[47]  R. Dummer,et al.  Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. , 2004, Archives of dermatology.

[48]  D. Horsman,et al.  Correlation between karyotype and quantitative immunophenotype in acute myelogenous leukemia with t(8;21) , 2004, Modern Pathology.

[49]  F. Mandelli,et al.  Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. , 2004, Blood.

[50]  L. Allen.  Stem cells. , 2003, The New England journal of medicine.

[51]  G. Ehninger,et al.  Analysis of Flt3-activating Mutations in 979 Patients with Acute Myelogenous Leukemia: Association with Fab Subtypes and Identification of Subgroups with Poor Prognosis , 2022 .

[52]  G. McDonald,et al.  Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. , 2002, Blood.

[53]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[54]  I. Bernstein,et al.  Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  C. Bloomfield,et al.  High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). , 2001, Blood.

[56]  X. H. Chen,et al.  Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[57]  A. Aventín,et al.  Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. , 2001, Haematologica.

[58]  D. Howard,et al.  The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells , 2000, Leukemia.

[59]  J. Ritz,et al.  Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. , 1992, Blood.

[60]  D. Scheinberg,et al.  Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia. , 1989, Leukemia.

[61]  H. Zola,et al.  Further characterization of human myeloid antigens (gp160,95; gp150; gp67): investigation of epitopic heterogeneity and non‐haemopoietic distribution using panels of monoclonal antibodies belonging to CD‐11b, CD‐13 and CD‐33 , 1988, British journal of haematology.

[62]  I. Bernstein,et al.  The L4F3 antigen is expressed by unipotent and multipotent colony-forming cells but not by their precursors. , 1986, Blood.

[63]  I. Bernstein,et al.  Expression of normal myeloid-associated antigens by acute leukemia cells. , 1986, Blood.

[64]  J. Griffin,et al.  A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. , 1984, Leukemia research.